Protandim Supplement Anti-Aging Drug Causes Surge in Stock Price for Parent Company Lifevantage Corporation

In less than a 30 day period, the stock price of the Lifevantage Corporation (LFVN) rose by over 19% based on some changes in management and board of directors. The stock which currently resides at about a dollar and a half is still a good buy according to analysts based on the performance of its primary product, Protandim.

Protandim is a dietary supplement which has been clinically proven to reduce the effects of oxidative stress, as well as the progressive rate of cellular aging according to the company. Secondary to the Protandim is LifeVantage TrueScience Anti-Aging Cream.

LifeVantage, dietary supplement company which currently holds four patents for Protandim, is reportedly also researching and developing products to address such issues as altitude sickness, skin cancer, photo aging of the skin, renal failure, osteoarthritis, HIV/AIDS-associated lipodystrophy, pulmonary hypertension, periodontal disease, heart disease, coronary artery bypass graft failure, asthma, Duchenne muscular dystrophy, metabolic syndrome, non-alcoholic fatty liver disease, and optic neuropathy.

Lifevantage held its annual shareholders meeting on January 10th. The results of the meeting, which included adding four new board members, appears to be what has spurred the recent increase in stock prices.

According to information released by the company, the new board gathered after the shareholder meeting and appointed Woody Spedden as the new Chairman of the Board.

Q2 financial results for LFVN are expected to be released after the close on Valentines Day next week. Just a few months ago the company increased its 2012 fincal outlook saying that it expects revenues of $95-$105 million versus previous estimates of $80 to $90 million. Similarly operating income projections were also raised by about $3-$5 million.